Literature DB >> 1717587

N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes.

P Botarelli1, B A Houlden, N L Haigwood, C Servis, D Montagna, S Abrignani.   

Abstract

The HIV envelope protein gp120 is heavily glycosylated, having 55% of its molecular mass contributed by N-linked carbohydrates. We investigated the role of N-glycosylation in presentation of HIV-gp120 to T cells. T cell clones obtained from humans immunized with a recombinant nonglycosylated form of HIV-gp120 (env 2-3) were studied for their ability to recognize both env 2-3 and glycosylated gp120. We found that 20% of CD4+ T cell clones specific for env 2-3 fail to respond to glycosylated gp120 of the same HIV isolate. Using synthetic peptides, we mapped one of the epitopes recognized by such clones to the sequence 292-300 (NESVAINCT), which contains two asparagines that are glycosylated in the native gp120. These findings suggest that N-linked carbohydrates within an epitope can function as hindering structures that limit Ag recognition by T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717587

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Viral glycoprotein heterogeneity-enhancement of functional diversity.

Authors:  I T Schulze; I D Manger
Journal:  Glycoconj J       Date:  1992-04       Impact factor: 2.916

2.  Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.

Authors:  W M Blay; S Gnanakaran; B Foley; N A Doria-Rose; B T Korber; N L Haigwood
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 3.  Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view.

Authors:  S Abrignani
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Modulation of gene expression in CD4+ T lymphocytes following in vitro HIV infection: a comparison between human and chimpanzee.

Authors:  Pol-André Apoil; Arnaud Gleizes; Bénédicte Puissant-Lubrano; Lionel Forestier; Raymond Julien; Peter Winterton; Christophe Pasquier; Jacques Izopet; Antoine Blancher
Journal:  Virusdisease       Date:  2015-06-06

5.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Authors:  N A Doria-Rose; G H Learn; A G Rodrigo; D C Nickle; F Li; M Mahalanabis; M T Hensel; S McLaughlin; P F Edmonson; D Montefiori; S W Barnett; N L Haigwood; J I Mullins
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Subtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120.

Authors:  R Shyama Prasad Rao; Bernd Wollenweber
Journal:  Int J Biol Sci       Date:  2010-07-21       Impact factor: 6.580

8.  Molecular cloning and characterization of an immunosuppressive and weakly oncogenic variant of Friend murine leukemia virus, FIS-2.

Authors:  H Y Dai; A Faxvaag; G I Troseth; H Aarset; A Dalen
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing.

Authors:  Peter C Chien; Sandra Cohen; Michael Tuen; James Arthos; Pei-de Chen; Sukeshi Patel; Catarina E Hioe
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

Authors:  Joseph G Joyce; Isaac J Krauss; Hong C Song; David W Opalka; Karen M Grimm; Deborah D Nahas; Mark T Esser; Renee Hrin; Meizhen Feng; Vadim Y Dudkin; Michael Chastain; John W Shiver; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.